



COVID-19: New ICD-10 Diagnosis Codes Updates for Texas Medicaid Effective 04/01/2022

April 13, 2022

What is new

Effective for dates of service on or after April 1, 2022, in response to the COVID-19 public health emergency, the Center for Disease Control and Prevention's (CDC), the National Centers for Health Statistics (NCHS) added three new diagnosis codes and the Centers for Medicare and Medicaid Services (CMS) added nine new Procedure Coding System (PCS) for inpatient hospital surgical procedure codes into the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). See notice from [Texas Medicaid and Healthcare Partnership \(TMHP\)](#) for more info.

Effective date and ICD-10-CM codes

These three new ICD-10-CM diagnosis codes are effective for dates of service on or after April 1, 2022.

ICD-10-CM Codes	Description
Z28310	Unvaccinated for COVID-19
Z28311	Partially vaccinated for COVID-19
Z2839	Other underimmunization status

Effective date and ICD-10-PCS codes

These nine new ICD-10-PCS diagnosis codes for inpatient hospital surgical procedure codes are effective for dates of service on or after April 1, 2022, and should be submitted only on inpatient hospital claims (as applicable):

ICD-10-CM Codes	Description
XW013V7	Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
XW013W7	Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
XW023V7	Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
XW023W7	Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
XW023X7	Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
XW023Y7	Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
XW0DXR7	Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7
XW0G7R7	Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7

XW0H7R7	Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7
---------	-------------------------------------------------------------------------------------------------------

Note: These procedure codes are surgical codes used to assign the proper Diagnosis -Related Group (DRG) for inpatient hospital stay and are processed as information only.

Questions:

For questions or additional information, please:

- Contact your BCBSTX Medicaid Network Team at **1-855-212-1615**, or
- Submit via email to [Texas Medicaid Network Department](#)

The above material is for informational purposes only and is not intended to be a substitute for the independent medical judgment of a physician. Physicians and other health care providers are encouraged to use their own best medical judgment based upon all available information and the condition of the patient in determining the best course of treatment.